Dermapharm Holding SE (CHIX:DMPD) Moat Score: 5/10 (As of Jun. 30, 2026)


CHIX:DMPD Dermapharm Holding SE CHIX:DMPD
80 GF Score
Price €46.18
GF Value €38.59
! 9 Warning Signs
View Full Analysis

What is Dermapharm Holding SE Moat Score?

Dermapharm Holding SE CHIX:DMPD 80 Moat Score is 5 as of Jun. 30, 2026. GuruFocus rates CHIX:DMPD with a GF Score™ of 80/100 and a GF Value™ of €38.59. The stock has 9 warning signs investors should review. Among 1,030 Drug Manufacturers companies, Dermapharm Holding SE ranks better than 94.66% on this metric.

Dermapharm Holding SE has the Moat Score of 5, which implies that the company might have Narrow Moat - Solid narrow moat.

Dermapharm Holding SE has Narrow Moat: Dermapharm has a solid narrow moat due to its strong brand in the pharmaceutical sector and valuable intellectual property. It benefits from economies of scale and a robust distribution network, but faces competition that limits its pricing power and market share.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Dermapharm Holding SE might have Narrow Moat - Solid narrow moat.

Dermapharm Holding SE  (CHIX:DMPd) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Dermapharm Holding SE Moat Score Related Terms

CHIX:DMPD vs ZTS, UTHR, VTRS: Moat Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Dermapharm Holding SE's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Dermapharm Holding SE Moat Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Dermapharm Holding SE's Moat Score distribution charts can be found below:

* The bar in red indicates where Dermapharm Holding SE's Moat Score falls into.


CHIX:DMPD
80GF Score
Dermapharm Holding SE CHIX:DMPD
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 5 mean?
Dermapharm Holding SE (CHIX:DMPD) has a Moat Score of 5 as of Jun. 30, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Dermapharm Holding SE ranks #55 out of 1030 companies in the Drug Manufacturers industry, placing it in the top 5.3%.
Is Dermapharm Holding SE's Moat Score too high?
Dermapharm Holding SE's current Moat Score is 5. Based on the distribution chart, Dermapharm Holding SE ranks #55 out of 1030 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Dermapharm Holding SE has a GF Score™ of 80/100, reflecting its overall financial health beyond just this single metric.
How does Dermapharm Holding SE's Moat Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Dermapharm Holding SE ranks #55 out of 1030 companies for Moat Score. This places Dermapharm Holding SE in the top 5% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Drug Manufacturers company?
A good Moat Score depends on the Drug Manufacturers industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Dermapharm Holding SE's current Moat Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dermapharm Holding SE stock overvalued right now?
Dermapharm Holding SE (CHIX:DMPD) has a current Moat Score of 5. The stock's GF Value™ is €38.59, compared to a current price of €46.18 — trading 19.7% above its estimated fair value. The current Moat Score is 5. Dermapharm Holding SE's overall GF Score™ is 80/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Dermapharm Holding SE (CHIX:DMPD), the current Moat Score is 5 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Dermapharm Holding SE (CHIX:DMPD) Overvalued in 2026?

Based on GuruFocus' analysis, Dermapharm Holding SE stock appears to be overvalued. The current stock price of €46.18 is trading 19.7% above its estimated GF Value™ of €38.59.

Key valuation signals for CHIX:DMPD:

  • Moat Score: 5
  • GF Value™: €38.59 vs. price of €46.18 (19.7% above fair value)
  • GF Score™: 80/100 with 9 warning signs

No single metric tells the full story. See the CHIX:DMPD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Dermapharm Holding SE Business Description

Other Exchanges DMPHF:USA0A5J:UKDMP:Germany
Address Lil-Dagover-Ring 7, Grunwald, BY, DEU, 82031
Dermapharm Holding SE manufactures patent-free branded pharmaceuticals for selected therapy fields, over-the-counter drugs, and natural remedies. The portfolio of the company includes cosmetics, nutritional supplements, and diet and medical devices. Business operating segments include Branded pharmaceuticals, which drive key revenue, Other healthcare products, and Parallel import business. The Branded pharmaceuticals segment covers numerous product areas through a wide variety of items sold under reputable brand names.
80GF Score

Get the complete analysis for CHIX:DMPD

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€46.18
Price
€38.59
GF Value